A man named Jim Cramer talked about some companies and how they did in the past year. He said one company called Axsome Therapeutics did a great job and made lots of money, so he was happy with them. But he didn't like two other companies, SolarEdge and Enphase, because they are too hard to own or buy for people. One reason is that they cut some jobs, which means less people work there now. Another company called Goldman Sachs also said that SolarEdge is not a good choice to buy. Read from source...

- Cramer praises Axsome Therapeutics for its amazing quarter and high revenue, but fails to mention the significant dilution of shareholders that occurred due to multiple equity offerings and convertible debt issuance. This is a relevant factor that affects the future earnings potential and value of the company, yet Cramer ignores it in his praise.
- Cramer also claims that SolarEdge is too hard to own, without providing any clear reasoning or evidence to support this statement. He seems to be influenced by personal feelings or emotions rather than rational analysis. This shows a lack of objectivity and professionalism on his part.
- The article compares Axsome Therapeutics with SolarEdge Technologies, but they are in different industries and have different business models. It is not fair to compare them directly without adjusting for the differences in their growth prospects, risks, and competitive advantages. This creates a false impression of similarity and makes it harder for investors to make informed decisions based on the article.

Do you want me to generate a table that summarizes the main points of this article and compares different stocks or ETFs?